$PRTK PR from PRTK HAS to be coming out shortly......... “This NDA is our third submission accepted for review by the China NMPA and our first anti-infective NDA and demonstrates our capabilities in therapeutic areas outside of oncology. The Chinese infectious disease market is significantly underserved, and innovation is desperately needed more than ever due to the rise in bacterial resistance.” Dr. Harald Reinhart, Chief Medical Officer for Autoimmune and Infectious Diseases at Zai Lab added, “Omadacycline is particularly well positioned for the China market due to its broad activity covering a wide spectrum of pathogens (including multi-drug resistance) associated with CABP and ABSSSI.... There are limited treatment options against drug-resistant bacteria in China, and omadacycline is an innovative drug that can address such unmet medical needs.”
  • 5
  • 1